Dilaudid-hp side effects by duration, gender and age - a phase IV clinical study of FDA data
Summary:
Side effects are reported by people who take Dilaudid-hp. Common side effects include injection site necrosis among females, and agitation among males.
The phase IV clinical study is created by eHealthMe based on 86 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
86 people who take Dilaudid-Hp and have side effects are studied.
What is Dilaudid-Hp?
Dilaudid-hp has active ingredients of hydromorphone hydrochloride. It is used in pain. Currently, eHealthMe is studying from 112 Dilaudid-hp users.
Number of Dilaudid-hp reports submitted per year:

Dilaudid-Hp side effects by time on the drug*:
< 1 month:
- Apnoeic attack
- Death
- Drug administration error
- Respiratory depression (respiration has a rate below 12 breaths)
- Abdominal pain
- Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
- Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
- Blood creatinine increased
- Blood in stool
- Bradycardia (abnormally slow heart action)
1 - 6 months:
- Cancer pain
6 - 12 months:
n/a
1 - 2 years:
n/a
2 - 5 years:
n/a
5 - 10 years:
n/a
10+ years:
n/a
not specified:
- Respiratory depression (respiration has a rate below 12 breaths)
- Agitation (state of anxiety or nervous excitement)
- Death
- Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
- Injection site necrosis (death of body tissue at injection site)
- Arachnoiditis (neuropathic disease caused by inflammation of the arachnoid)
- Chest discomfort
- Dehydration (dryness resulting from the removal of water)
- Drug maladministration
- Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
Dilaudid-Hp side effects by gender *:
female:
- Injection site necrosis (death of body tissue at injection site)
- Respiratory depression (respiration has a rate below 12 breaths)
- Apnoeic attack
- Arachnoiditis (neuropathic disease caused by inflammation of the arachnoid)
- Chest discomfort
- Death
- Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
- Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
- Abasia (inability to walk)
- Abdominal pain
male:
- Agitation (state of anxiety or nervous excitement)
- Cancer pain
- Cardiac valve disease (heart valve disease)
- Dehydration (dryness resulting from the removal of water)
- Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
- General symptom
- Malignant neoplasm progression (cancer tumour came back)
- Nervous system disorder (a general class of medical conditions affecting the nervous system)
- Pruritus (severe itching of the skin)
- Restlessness (not able to rest)
Dilaudid-Hp side effects by age (0-1 to 60+) *:
0-1:
n/a
2-9:
n/a
10-19:
- Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
- Brain damage
- Cholecystitis chronic (long lasting infection of gallbladder)
- Pruritus (severe itching of the skin)
- Respiratory depression (respiration has a rate below 12 breaths)
20-29:
- Death
- Drug administration error
- General physical health deterioration (weak health status)
- Injection site necrosis (death of body tissue at injection site)
30-39:
- Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
- Brain injury
40-49:
- Arachnoiditis (neuropathic disease caused by inflammation of the arachnoid)
- Abdominal pain
- Abscess (pus)
- Collapse (sudden functional breakdown)
- Hypoaesthesia (reduced sense of touch or sensation)
- Nervous system disorder (a general class of medical conditions affecting the nervous system)
- Respiratory depression (respiration has a rate below 12 breaths)
50-59:
- Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
- Acute circulatory failure (shock)
- Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
- Brain death
- Cardiac discomfort
- Drug ineffective
- Malignant neoplasm progression (cancer tumour came back)
- Respiratory depression (respiration has a rate below 12 breaths)
60+:
- Agitation (state of anxiety or nervous excitement)
- Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
- Application site mass
- Back pain
- Blood calcium decreased
- Blood creatinine increased
- Blood in stool
- Bradycardia (abnormally slow heart action)
- Cellulitis (infection under the skin)
- Death
* Approximation only. Some reports may have incomplete information.
Do you take Dilaudid-hp?
Personalize this study to your gender and ageHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How the study uses the data?
The study is based on hydromorphone hydrochloride (the active ingredients of Dilaudid-hp) and Dilaudid-hp (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.
Related studies
Alternative drugs to, pros and cons of Dilaudid-hp:
- Dilaudid-hp (112 reports)
All Dilaudid-hp side effects from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zWho is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Fragmin and Prochlorperazine Edisylate drug interaction - 7 seconds ago
- Rapamune and Multihance drug interaction - 19 seconds ago
- Rapaflo and Xeljanz Xr drug interaction - 24 seconds ago
- Aciphex and Benadryl drug interaction - 25 seconds ago
- Tegretol and Ammonia Increased - 33 seconds ago
- Olanzapine and Milk Thistle drug interaction - 34 seconds ago
- Rapaflo and Flomax drug interaction - 37 seconds ago
- Alvesco and Crohn'S Disease - 44 seconds ago
- Ranexa and Coreg drug interaction - a minute ago
- Ramelteon and Bisoprolol Fumarate drug interaction - a minute ago